PhD, University of New South Wales
MA, Sociology & Statistics, McGill Univeristy, Canada
BS, Psychology, Drexel University, USA
Dr. Benjamin Daniels is an early-career pharmacoepidemiologist, specialising the analysis of linked administrative health data to understand the use and outcomes of medicines, with a particular focus on targeted cancer therapies. Ben has over 10 years' experience as a biostatistician and analyst, leading statistical analyses for multi-disciplinary research teams spanning laboratory-based, epidemiology, and public health research at UNSW and the University of Sydney. He is currently a Research Fellow within the Medicines Policy Research Unit at the Centre for Big Data Research in Health (CBDRH) at UNSW, where he also completed his PhD in 2018. His current and past projects include a comprehensive examination of the treatment and outcomes in women treated with trastuzumab for metastatic breast cancer through the Herceptin Program in Australia (2001 - 2015) and ongoing research into the use and outcomes associated with HER2-targeted therapies; determining the risk of developing skin cancer associated with high blood pressure medications; trajectories of multiple medicine use and opioid use surrounding cancer diagnosis; and evaluating the impact of national policies for proton pump inhibitor and opioid medicines.
2020 - UNSW Medicine Early Career Academic Network (ECAN) Best Paper Award - Public Health
NHMRC Ideas Grant, "Disentangling the interrelationship between multimordibity, multimedicine use, and cardiovascular health" (Associate Investigator) (2021 - 2023)
NHMRC Post-graduate scholarship (2015-2018)